Please login to the form below

Not currently logged in
Email:
Password:

Neurocentrx appoints two members to the board

Nigel Brooksby and Dr Tim Corn join the pharma group

Nigel BrooksbyNeurocentrx, a UK-based pharmaceutical company, has appointed Nigel Brooksby (pictured right) as non-executive chairman.

Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.

His career history has seen him work in private equity and venture capital and he has been president of the ABPI.

Brooksby said: “My focus is to accelerate the business model and drive commercial clinical trials to raise international awareness of what we are offering, and enter the global market.

“I look forward to working the team, and helping to drive the company to an exciting new stage in their development.”

Joining Brooksby is EUSA Pharma’s former chief medical officer Dr Tim Corn, who becomes the pharma group’s non-executive director.

Carmel Reilly, chief executive officer of Neurocentrx, said: “I am honoured to welcome the extraordinary talents of Nigel and Tim onto the board.

“This is an important milestone for Neurocentrx and marks the start of an exciting new phase of our growth.”

13th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics